IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

Détails

ID Serval
serval:BIB_AD55EB9730D6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
Périodique
Journal of Hepatology
Auteur(s)
Lange C.M., Zeuzem S.
ISSN
0168-8278 (Print)
ISSN-L
0168-8278
Statut éditorial
Publié
Date de publication
2011
Volume
55
Numéro
3
Pages
692-701
Langue
anglais
Résumé
Recent genome-wide association studies (GWAS) have identified genetic variations near the IL28B gene which are strongly associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. Protective IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients. In HCV genotype 1 patients, IL28B variations were shown to be the strongest pre-treatment predictor of virologic response. In the treatment of HCV genotype 2 and 3 infected patients, IL28B variations play only a minor role. Preliminary data indicate that IL28B variations are also associated with treatment outcome of regimens, including directly acting antiviral (DAA) agents, though their impact seems to be attenuated compared to standard treatment. Here, we review these important findings and discuss possible implications for clinical decision making in the treatment of HCV infection.
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/09/2011 9:35
Dernière modification de la notice
20/08/2019 16:17
Données d'usage